CM326

Phase 3Biologic

KKeymed Biosciences Co.Ltd

CM326 is one of 96 biologic programs targeting Chronic Rhinosinusitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic RhinosinusitisActive, not recruiting

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaActive, not recruiting

Chronic RhinosinusitisPhase 2

Active, not recruiting

Chronic Rhinosinusitis With Nasal PolypsPhase 1/Phase 2

Active, not recruiting

Atopic DermatitisPhase 1/Phase 2

Active, not recruiting

AsthmaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

CM326

KKeymed Biosciences Co.Ltd

Phase 3

2 2

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 3

Cinqair

Teva

Preclinical

13 4

Asmanex

Novartis

Preclinical

5 5

Celexa

AbbVie

Preclinical

1 6

Spiriva

Boehringer Ingelheim

Preclinical

8 7

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 8

Aciphex

Akero Therapeutics

Preclinical

2 9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

1 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Not yet recruiting

Chronic Rhinosinusitis

NCT07420257

Q1 2029

Phase 3Not yet recruiting

Asthma

NCT07372287

Clinical

Trials by Indication[1]

Atopic Dermatitis3 trials

The Study of CM326 in Adult Subjects With Atopic Dermatitis

Unknown status·KKeymed Biosciences Co.Ltd·Phase 2·NCT05671445·100 enrolled

The Study of CM326 in Moderate-to-severe Atopic Dermatitis

Unknown status·KKeymed Biosciences Co.Ltd·Phase 2·NCT05671432·240 enrolled

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

Unknown status·KKeymed Biosciences Co.Ltd·Phase 1/2·NCT05186922·54 enrolled

Chronic Rhinosinusitis2 trials

Study of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Not yet recruiting·KKeymed Biosciences Co.Ltd·Phase 2·NCT06372678·90 enrolled

A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis

Not yet recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT07420257·212 enrolled

Asthma2 trials

A Study of CM326 in Subjects With Moderate to Severe Asthma

Unknown status· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05774340·207 enrolled

A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

Not yet recruiting·CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.·Phase 3·NCT07372287·230 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study of CM326 in Healthy Volunteers

Completed·KKeymed Biosciences Co.Ltd·Phase 1·NCT04842201·44 enrolled

Chronic Rhinosinusitis With Nasal Polyps1 trial

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

Completed·KKeymed Biosciences Co.Ltd·Phase 1/2·NCT05324137·88 enrolled

1 more indication

Unspecified2 trials

A Multiple Ascending Doses Study of CM326 Injection in Healthy Subjects

Completed·KKeymed Biosciences Co.Ltd·Phase 1·NCT05171348·40 enrolled

Study of CM326 Injection in Healthy Subjects

Completed·KKeymed Biosciences Co.Ltd·Phase 1·NCT05715333·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for CM326. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CM326 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CM326. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Keymed Biosciences Co.Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: KKeymed Biosciences Co.Ltd

CM326

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q1 2029

Trials by Indication[1]

Atopic Dermatitis3 trials

Chronic Rhinosinusitis2 trials

Asthma2 trials

Single Ascending Dose1 trial

Chronic Rhinosinusitis With Nasal Polyps1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News